GLPG
HealthcareGalapagos NV
$32.74
$-0.23 (-0.70%)
Jan 5, 2026
Price History (1Y)
Analysis
Galapagos NV is a healthcare company operating in the biotechnology sector. The company has a significant market presence with a market capitalization of $2.16 billion and employs 704 individuals. Financially, Galapagos NV has reported negative profitability metrics, including a gross margin of -72.2%, an operating margin of -58.6%, and a profit margin of -151.9%. The company's returns on equity (ROE) and return on assets (ROA) are also negative at -16.7% and -5.2%, respectively. Galapagos NV has cash reserves of $3.05 billion, but owes $7.50 million in debt. Galapagos NV's valuation is characterized by a forward P/E ratio of 104.58 and a price to sales ratio of 7.52. The company's revenue growth over the past year was 18.9%, but earnings growth data is not available.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Galapagos NV
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Visit website →Key Statistics
- Market Cap
- $2.16B
- P/E Ratio
- N/A
- 52-Week High
- $37.78
- 52-Week Low
- $22.36
- Avg Volume
- 146.85K
- Beta
- 0.04
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- Belgium
- Employees
- 704